Evidence map›Paper›PMID 31557166›Full record

ArticlePloS one2019

Antitumor activity of a novel dual functional podophyllotoxin derivative involved PI3K/AKT/mTOR pathway.

Yongli Li, Tengfei Huang, Yun Fu, Tingting Wang, Tiesuo Zhao, Sheng Guo, Yanjie Sun, Yun Yang, Changzheng Li

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Yongli LiCollege of Basic Medical Science, Sanquan College of Xinxiang Medical University, Xinxiang, Henan, P. R. China.
Tengfei HuangCollege of Basic Medical Science, Xinxiang Medical University, Xinxiang, Henan, P. R. China.
Yun FuCollege of Basic Medical Science, Xinxiang Medical University, Xinxiang, Henan, P. R. China.
Tingting WangCollege of Basic Medical Science, Xinxiang Medical University, Xinxiang, Henan, P. R. China.
Tiesuo ZhaoCollege of Basic Medical Science, Xinxiang Medical University, Xinxiang, Henan, P. R. China.
Sheng GuoCollege of Basic Medical Science, Xinxiang Medical University, Xinxiang, Henan, P. R. China.
Yanjie SunExperimental Teaching Center of Biology and Basic Medicine, Sanquan College of Xinxiang Medical University, Xinxiang, Henan, P. R. China.
Yun YangCollege of Basic Medical Science, Xinxiang Medical University, Xinxiang, Henan, P. R. China.
Changzheng LiCollege of Basic Medical Science, Xinxiang Medical University, Xinxiang, Henan, P. R. China.ORCID 0000-0002-6226-5843
Xinxiang Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The progression of cancer through local expansion and metastasis is well recognized, but preventing these characteristic cancer processes is challenging. To this end, a new strategy is required. In this study, we presented a novel dual functional podophyllotoxin derivative, 2-pyridinealdehyde hydrazone dithiocarbamate S-propionate podophyllotoxin ester (PtoxPdp), which inhibited both matrix metalloproteinases and Topoisomerase II. This new podophyllotoxin derivative exhibited significant anti-proliferative, anti-metastatic that correlated with the downregulation of matrix metalloproteinase. In a xenograft animal local expansion model, PtoxPdp was superior to etoposide in tumor repression. A preliminary mechanistic study revealed that PtoxPdp induced apoptosis and autophagy via the PI3K/AKT/mTOR pathway. Furthermore, PtoxPdp could also inhibit epithelial-mesenchymal transition, which was achieved by downregulating both PI3K/AKT/mTOR and NF-κB/Snail pathways. Taken together, our results reveal that PtoxPdp is a promising antitumor drug candidate.

Indexed as

AnimalsAntineoplastic AgentsEpithelial-Mesenchymal TransitionFemaleHep G2 CellsHumansMatrix Metalloproteinase InhibitorsMiceMice, Inbred BALB CNeoplasms, ExperimentalNF-kappa BPhosphatidylinositol 3-KinasesPodophyllotoxinProtein Kinase InhibitorsProto-Oncogene Proteins c-aktSignal TransductionAntineoplastic AgentsMatrix Metalloproteinase InhibitorsNF-kappa BPhosphatidylinositol 3-KinasesPodophyllotoxinProtein Kinase InhibitorsProto-Oncogene Proteins c-aktSNAI1 protein, humanSnail Family Transcription FactorsTOR Serine-Threonine Kinases

Identifiers

PMID31557166
PMCPMC6763125
OpenAlexW2975561025

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.